Cystic fibrosis (CF) is a genetic disease caused by mutations in the cystic fibrosis transmembrane regulator (CFTR) gene resulting in absent or deficient expression and function of CFTR protein. 1 2 The main cause of morbidity and mortality in CF is linked to a chronic inflammatory and infectious airway process which leads to progressive bronchial epithelial damage and lung destruction. 3 4 Defective electrolyte transport is believed to be the initial abnormality in CF disease resulting in alteration of the epithelial secretions. Evidence of an early and intense airway inflammation, probably even in the absence of documented infection, has been reported in several studies. 5 6 A possible role of CFTR dysfunction in the induction and maintenance of the inflammatory and infectious process through a dysregulation of epithelial ion transport and abnormal extracellular fluid has been suggested. 7 8 It has recently been reported that CFTR may also be involved in the apoptotic process of epithelial cells. 9 10 Apoptosis is a physiological process essential for the maintenance of homeostasis of epithelial organisation and function, and for clearance of inflammatory cells. Apoptosis is regulated by several factors including oxidative stress, 11 extracellular matrix proteins, 12 and external signals such as Fas ligation. 13 Fas receptor (CD95/APO1) belongs to the tumour necrosis factor (TNF) receptor superfamily. It is commonly expressed on lymphocytes as well as on the cell surface of various epithelial cells mediating interactions with immune eVector cells. 14 Fas receptor activation by its ligand (Fas ligand) induces apoptosis of Fas bearing cells. Fas ligand (FasL) belongs to the TNF family and is predominantly expressed on activated T cells. 15 The expression of FasL in sites such as the eye and in some human carcinomas contributes to the existence of "immune privilege" of these tissues by inducing apoptosis in Fas bearing immune cells. 16 17 Its expression in epithelial tissue suggests a role for FasL in controlling epithelial tissue injury during various inflammatory states. 18 As described for TNF-, there is a soluble form of FasL obtained by conversion of membrane bound FasL through a proteolytic process and devoid of apoptotic activity. 19 In this study we examined (1) the epithelial expression of Fas and Fas ligand in bronchial samples obtained from CF patients and non-CF patient controls; (2) the expression of Fas/FasL in two human tracheal epithelial cell lines, one of them with a CF genotype and the other with the normal CFTR genotype; and (3) the serum concentrations of soluble FasL in patients with CF and healthy controls.
Methods

IMMUNOHISTOCHEMICAL STUDY
Patients
Between 1993 and 1997 eight patients with CF (2M:6F) of mean age 16 (range 6-30) underwent bronchial biopsies (five patients) or lobectomy (three patients) because of repeated infectious complications with localised bronchiectasis. Patient characteristics and recruitment have been previously described. 20 Four patients carried F508/ F508 mutations and four F508/other mutations. Forced expiratory volume in one second (FEV 1 ) varied from 26% to 86% predicted and forced vital capacity (FVC) from 32% to 99% predicted. Two patients had chronic sputum colonisation with Staphylococcus aureus, the others with Pseudomonas aeruginosa.
Four male subjects who underwent lobectomy for bronchial carcinoma were used as controls using non-neoplastic bronchial samples.
Bronchial tissues
The fibreoptic bronchial biopsy specimens and selected samples of bronchi obtained from surgical lobectomies were embedded in OCT compound (Tissue Tek), snap frozen in liquid nitrogen, and stored at -80°C until cryosectioning.
Immunohistochemistry: antigen expression and detection of DNA fragmentation
Five µm cryostat tissue sections were mounted onto poly-L-lysine coated slides and stored at -20°C. The slides were air dried for 30 minutes and fixed in 4% paraformaldehyde for 30 minutes. Tissue sections were incubated with antiFas monoclonal antibody (UB2, Immunotech SA, Marseille, France) at a 1:500 dilution in PBS/Triton 2% for one hour at room temperature. PBS/Triton 2% was substituted for the primary antibody for the negative controls. Samples were then washed extensively in Tris buVer 0.1 M and incubated for 30 minutes with a rabbit anti-mouse secondary antibody at a dilution of 1:25. After washing, samples were incubated with a mouse monoclonal alkaline phosphatase anti-alkaline phosphatase antibody (Sigma Immuno Chemicals, St Louis, Missouri, USA) at a dilution of 1:50 for 30 minutes sheltered from light. Detection of antibody was visualised with the Fast TM Fast Red TR naphthol substrate (Sigma Immuno Chemicals). Tissue sections incubated with mouse monoclonal alkaline phosphatase antialkaline phosphatase antibody alone served as negative controls.
For FasL staining, tissue sections were incubated for 30 minutes in H 2 O 2 0.3% washed in Tris buVer and incubated with anti-FasL rabbit polyclonal antibody (SC956; Santa Cruz Biotechnologies, Santa Cruz, California, USA) at a dilution of 1:100 for one hour. After washing a peroxidase conjugated secondary antibody at a 1:500 dilution was applied for one hour. Detection of antibody was visualised with 3,3'-diaminobenzidine in Tris buVer. Tissue sections incubated with the peroxidase conjugated secondary antibody served as negative control. FasL antibody was used in the presence or absence of the corresponding blocking peptide (amino acid residues 2-19, Santa Cruz Biotechnologies) to confirm the specificity of the staining.
To detect DNA fragmentation in bronchial epithelium the terminal deoxynucleotidyl transferase (TdT) mediated dUTP nick end labelling (TUNEL) method using an in situ cell death detection kit, fluorescein, and peroxidase antifluorescein antibody (Boehringer Mannheim) was used in four patients with CF and controls.
FAS AND FAS LIGAND EXPRESSION IN AIRWAY CELL LINES
Cultures of cell lines
Two human fetal SV40 transformed tracheal epithelial cell (HTEC) lines were studied-one with the CF genotype CFT-2 homozygous for F508 mutations and one wild CFTR genotype cell line (NT) used as a control. 21 The two HTEC lines were cultured in DMEM-HAMF12 medium (Gibco) supplemented with 10% fetal calf serum (Gibco) and 1% penicillin/streptomycin/fungizon (Sigma) at 37°C in a 5% CO 2 atmosphere.
Immunofluorescence staining and flow cytometric analysis Surface antigen expression was studied in unstimulated HTEC lines and in HTEC lines treated with TNF-(100 U/ml, Sigma) or interferon gamma (IFN-) (1000 U/ml, Genzyme) for 48 hours before immunofluorescence staining. The cells were removed from the dish with a solution containing versen and then washed in PBS. Mouse anti-human Fas monoclonal antibody (5 µg/ml, UB2, Immunotech SA) and rabbit anti-human FasL polyclonal antibody (SC956, 10 µg/ml, Santa Cruz Biotechnologies) were incubated with cells on ice for 45 minutes with concomitant permeabilisation with saparin for FasL staining. After washing with PBS/1% bovine serum albumin the cells were labelled with R-phycoerythrin (RPE) conjugated anti-mouse secondary antibody at a 1:100 dilution for Fas staining and fluorescein isothiocyanate (FITC) conjugated anti-rabbit antibody at a dilution of 1:50 for FasL staining. Cells were incubated in the dark for 45 minutes on ice, washed with PBS and resuspended before analysis by fluorescence activated cell sorting (FACS EPICS XL-MCL, Coulter). RPE and FITC conjugated alone and irrelevant isotype matched anti-human immunoglobulin served as negative controls. The mean (SD) fluorescence intensity was analysed. Six experiments were performed for statistical analysis for each antigen (Fas and FasL), each condition (basal condition and cytokine pretreatment), and each cell line (NT and CFT-2). The Wilcoxon signed rank test was used to compare the mean fluorescence intensity at basal conditions between NT and CFT-2 for Fas and FasL and the mean fluorescence intensity for Fas and FasL expression between basal and stimulated cells (IFN-or TNF-pretreatment) for each cell line.
MEASUREMENT OF SERUM SOLUBLE FAS LIGAND
Serum soluble FasL (sFasL) was measured in 21 successive patients with CF and 14 normal subjects (blood donor serum samples). Measures were obtained with the FasLigand ELISA kit (MBL Co Ltd, Nagoy, Japan). FasL was measured by sandwich ELISA. Samples were incubated in wells coated with the anti-FasL monoclonal antibody 4H9 for one hour. After washing, a peroxidase conjugated anti-FasL monoclonal antibody (4A5) was added and incubated for a further hour. An acid solution was then added to terminate the enzyme reaction and to stabilise the developed colour. The optical density (OD) of each well was measured at 450 nm using a microplate reader. The concentration of sFasL was calibrated from a dose response curve based on reference standards with a threshold detection concentration of 0.03 ng/ml. Because of possible undetectable values a Yates' 2 test was used to compare the partition of serum soluble FasL concentrations between CF patients and healthy controls. 
Results
IMMUNOHISTOCHEMISTRY
FasL was expressed with high intensity in all patients with CF, both in the ciliated epithelium and in the submucosal glandular epithelium, with diVuse cytoplasmic staining ( fig 1A  and B) . Both unistratified and epidermoid metaplastic epithelium gave an intense staining compared with controls ( fig 1C) . Fas antibody gave a membranous bronchial epithelial staining in normal and metaplastic epithelium and in submucosal glands, both in patients with CF and in controls, with no significant diVerence between them (fig 2A and B) . DNA fragmentation with intense intranuclear staining using TUNEL method was observed in some bronchial epithelial cells and submucosal glands of all CF samples but not in controls ( fig  3A and B) . However, the CF epithelium was not always well preserved and the interpretation of such a diVerence is diYcult. 
SERUM SOLUBLE FAS LIGAND
The serum concentration of FasL was very low in CF patients with undetectable concentrations (<0.03 ng/ml) in 13 of 21 patients. All the normal subjects had detectable concentrations of sFasL ranging from 0.08 to 0.38 ng/ml (p<0.001,Yates' 2 test). The median concentration was 0.125 ng/ml for normal subjects and was below the threshold detection value for patients with CF (fig 4) . The undetectable concentrations were not associated with therapeutic drugs, particularly corticosteroids.
Discussion
Our results show that in vivo FasL expression is markedly intense in human CF bronchial epithelium compared with controls; Fas is expressed in both CF and control bronchial epithelium with a similar intensity. More intense DNA fragmentation is also observed in patients with CF relative to controls but sometimes in impaired epithelium. In the cultures both deficient and normal CFTR genotype human tracheal cell lines expressed Fas and FasL but the mean fluorescence intensity for FasL expression was higher in CF genotype cells. Cytokine stimulation did not modify Fas and FasL expression in the two cell lines examined. Serum soluble Fas ligand is unmeasurable or is present in very low concentrations in most patients with CF.
Our results are consistent with recent publications showing expression of both Fas and FasL in human airway epithelium. 22 23 However, in our study the immunohistochemical staining for FasL is intense in patients with CF but very low in controls. The results of HTEC expression are in agreement with immunohistochemical findings, showing a significantly increased expression of FasL in the CF genotype cell line. On the other hand, Fas expression is the same in both human tissue and HTEC lines.
Apoptosis dysfunction in cystic fibrosis has recently been suggested with varying results. Gottlieb et al reported a "resistance" in vitro in the initiation of apoptosis in a mutant CFTR epithelial mouse mammary cell line caused by an inability to obtain cytoplasmic acidification compared with the wild CFTR genotype cell line. 9 On the other hand, Maiuri et al observed increased DNA fragmentation 10 and increased Fas and FasL expression in CF enterocytes suggesting a possible role for Fas ligation in the induction of apoptosis in CF enterocytes. 24 The high level of FasL staining observed in vivo in CF bronchial epithelium suggests various hypotheses. Firstly, the implication of local and chronic inflammation in the induction of FasL expression: stimulation by cytokines in this study and others did not increase Fas and FasL expression 25 but other cytokines such as IL-8 present in CF airways could be implicated in vivo. 5 8 Secondly, normal bronchial epithelial cells are dependent on cell-matrix interactions to prevent apoptosis 26 ; moreover, extracellular matrix proteins can induce Fas expression in epithelial cells. 27 The major modifications in 
28-30
The significance of low levels of sFasL observed in patients with CF is unclear. The soluble trimeric form of FasL results from a metalloproteinase mediated proteolytic process in the extracellular domain of membrane bound FasL. 19 To date, high levels of sFasL and soluble Fas have been described in haematopoietic and non-haematopoietic human cancer, in autoimmune disease, in viral hepatitis, and in alcoholic liver disease. [31] [32] [33] Processing and release represent a downregulation of proapoptotic activity of membrane bound ligand. 19 34 Undetectable levels of the soluble form have not been described in other diseases; our results could suggest the maintenance of apoptotic activity.
The consequences of the expression of both Fas and FasL in the same epithelium are unclear. Similar findings have been reported recently in autoimmune diseases such as Hashimoto's thyroiditis and primary Sjörgen's syndrome, while cells from normal individuals only express Fas. 35 36 These results suggest that in autoimmune diseases a suicidal or fratricidal programmed cell death involving a Fas/FasL interaction occurs leading to epithelial cell destruction. A similar implication in CF epithelium remains to be demonstrated. Other studies in animal models and asthmatic patients suggest a potential role for FasL in modulating bronchial inflammation inducing apoptosis in immune cells during inflammatory reactions. 18 22 23 FasL expression may also play a part by maintaining an "immune privileged" status in sites such as the eye 16 and by conferring immune suppression in malignancy 17 inducing apoptosis of Fasbearing immune cells such as lymphocytes and dendritic cells. Another recent study showed that FasL also has pro-inflammatory eVects since it can stimulate polymorphonuclear neutrophils (PMNs); activated PMNs directly mediate cytolysis of FasL+ cells. 37 In CF the possible apoptotic interaction between PMNs and FasL+ airway epithelial cells is important since PMNs are the predominant phagocytes in bronchial secretions even in patients with clinically mild lung disease. 5 On the other hand, PMNs express both Fas and FasL and activation of the Fas pathway by Fas-FasL interaction is one of the mechanisms of PMN apoptosis. 38 PMNs are the major source of the increased quantity of DNA found in CF sputum which essentially contributes to the altered viscosity of CF airway secretions. 39 40 Another hypothesis could be that FasL+ CF airway epithelial cells activate Fas mediated apoptosis of PMNs thereby inducing enhanced DNA release and alterations in mucus viscoelasticity.
The mechanisms of induction of FasL expression in CF airway epithelial cells remain to be determined. Whether it contributes to airway tissue damage or to the clearance of inflammatory cells is not yet known.
